Negev Capital confident that big pharma will ultimately embrace psychedelics
News release
by
Negev Capital
London, UK
|
June 14, 2023 03:56 AM Eastern Daylight Time
Negev Capital partner Ken Belotsky speaks to Thomas Warner from Proactive about the opportunities presented by the psychedelic startup scene.
Belotsky describes the pharmaceutical market as "pretty conservative" overall, but says he believes that "soon we will see examples of M&A activity from big pharma into psychedelics, and as soon as it happens we will see a completely different [level of] interest from funds in the psychedelic space."
The interview concludes with Belotsky discussing Negev Capital's sponsorship of the upcoming PSYCH symposium in London.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
